NCT02236312.

Methods	Randomised, parallel‐design, double‐blind, phase II trial
Participants	350 participants, older than 18 years old, both gender. Inclusion criteria Moderate to very severe glabellar lines at maximum frown as assessed by the participant and the Investigator and at least mild glabellar lines at rest Exclusion Criteria Any previous treatment with any botulinum toxin Rhytids of the glabellar region that cannot be smoothed out by manually spreading the skin apart Any previous insertion of any permanent or semi‐permanent material, hyaluronic acid or collagen fillers to the glabellar region Any history of facial surgery above the lower orbital rim Any planned facial surgery or aesthetic procedure during the study period, ablative skin resurfacing or chemical peels above the lower orbital rim in the previous 12 months or during the study period Country: USA
Interventions	Intervention: AbobotulinumtoxinA 30 U, 45 U, and 60 U in glabellar region Comparator: placebo in glabellar region
Outcomes	Primary outcome Reduction of glabellar frown line severity on day 14 following treatment with botulinum toxin [Time Frame: 14 Days] [Designated as safety issue: no] Secondary outcome Reduction in glabellar frown line severity is derived separately for the Investigator and the participant assessment, using a validated photo scale, at maximum frown on day 14
Notes	Other study ID number: 43QM1313 Q‐med. This trial finished on June 2, 2016. We resent an email on July 25, 2019